Match Group Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Match Group Inc trades at $36.82 (market cap $8.45B), while State Street SPDR S&P Biotech ETF trades at $158.23. The key difference: Match Group Inc pays a 2.17% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Match Group Inc nearer its low. Which is the better fit depends on your goals.
| MTCH | XBI | |
|---|---|---|
Market Cap | $8.45B | — |
Sector | Media | Broad Market / Factor |
52-Week High | $41.24 | $164.28 |
52-Week Low | $28.90 | $86.92 |
Enterprise Value | $11.42B | — |
Dividend Yield | 2.17% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI, the SPDR S&P Biotech ETF, trades at $157.37, up 1.88% today, with a bullish technical signal from moving averages and strong momentum indicators. The ETF has surged nearly 17% in a month, driven by positive clinical trial news and increased M&A activity in the biotech sector. Analyst coverage is limited to one hold rating, reflecting cautious optimism amid high volatility.
Outlook remains positive due to sector tailwinds like AI-driven drug discovery and robust M&A, but risks include policy uncertainty and the fund's high beta. Investors should weigh the potential for continued growth against inherent volatility in small- and mid-cap biotech holdings.
Trailing returns across standard periods
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →